However, the observed co-expression gives further rationale for using a combination of immune checkpoint inhibitors such as anti-PD-1/anti-TIGIT or anti-PD-1/anti-CTLA-4 in the neoadjuvant setting for treatment of HNSCC. The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.